Mexdagry

Metformin Hydrochloride and Dapagliflozin, the active ingredient in Mexdagry, is a Biguanide; SGLT2 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH USA supplies Mexdagry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant distribution across multiple regions.

Mexdagry combines metformin and dapagliflozin to manage hyperglycemia in type 2 diabetes.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise: improves HbA1c when lifestyle measures alone are insufficient. - Combination with other antidiabetic agents: provides additional glucose reduction for patients inadequately controlled on monotherapy.

The following adverse reactions have been reported with the combination of metformin and dapagliflozin.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: loose stools, often transient. - Genital mycotic infection: increased risk in both sexes. - Urinary tract infection: symptoms of dysuria or frequency. - Increased urinary volume: polyuria due to glucosuria. - Abdominal discomfort: bloating or cramping.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Ketoacidosis: euglycaemic diabetic ketoacidosis may occur. - Severe dehydration: due to excessive fluid loss. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis. - Acute kidney injury: sudden decline in renal function. - Pancreatitis: inflammation of the pancreas.

When prescribing Mexdagry, clinicians should consider several safety measures.

- Renal function assessment: evaluate eGFR before initiating therapy. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: monitor for symptoms especially in renal dysfunction. - Genital infections: educate patients on hygiene to reduce risk. - Hypoglycemia risk: monitor when used with insulin or sulfonylureas. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mexdagry may interact with several concomitant medications.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of renal impairment. - Insulin or sulfonylureas: may cause severe hypoglycemia. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may affect volume status and renal function. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Alcohol: potentiates risk of lactic acidosis. - NSAIDs: may reduce renal clearance of metformin.